SRN-101 is an investigational therapy in development by Siren Biotechnology and has not been approved by the U.S. Food and Drug Administration (FDA).
Siren Biotechnology does not currently provide expanded access to SRN-101.
Due to the early stage of development, limited clinical data, and manufacturing considerations, SRN-101 is not available outside of FDA-authorized clinical trials.
Expanded Access Requests
Siren Biotechnology is not accepting expanded access requests for SRN-101 at this time.
If the policy changes, requests would be evaluated based on available safety data, stage of clinical development, manufacturing capacity, and potential impact on ongoing or planned clinical trials. We anticipate acknowledging receipt of inquiries within approximately 5–10 business days.
SRN-101 is not currently listed on ClinicalTrials.gov.
Contact: regulatory@sirenbiotechnology.com
This policy may be updated as development progresses.
Acknowledgement
10 Business Days
Siren Biotechnology
EA Policies for Single Patient